Gopinath Ranganna
2PUBLICATIONS
2CO-AUTHORS

Get your video featured.

Get your video featured.
Publications (2)
Sort by Publication Date:
|Sep 17, 2022
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study.Thomas C Blevins, Yaron Raiter, Bin Sun
|Aug 11, 2021
Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL-1601D with US and European insulin aspart in healthy volunteers: A randomized, double-blind, crossover, euglycaemic glucose clamp study.Ulrike Hövelmann, Yaron Raiter, Anoop Chullikana
Pageof 1

